Merck previews an early hit with Keytruda combo for kidney cancer, putting more pressure on rival Bristol-Myers
Merck arrived at ESMO in style, fronting their appearance in Munich with positive — and very early — combination data for their PD-1 checkpoint star Keytruda in treating frontline kidney cancer.
Researchers combined Keytruda with Pfizer’s Inlyta for KEYNOTE-426 and came away with an early win on both progression-free and overall survival, along with a key secondary in beating Sutent in a head-to-head showdown.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.